Just six weeks after taking the helm of biotech Advaxis, CEO Ken Berlin has launched a search for a partner for its stalled lead axalimogene filolisbac (AXAL) and will scale back trials of the immunotherapy in order to bring earlier stage programs forward
Shares of?Advaxis, Inc.?announced that the U.S. Food and Drug Administration?halted a Phase I/II trial?that uses an?AstraZeneca Pharmaceuticals LPdrug following the death of a patient.